Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramantamig plus daratumumab versus DVRd or DRd in transplant-ineligible newly diagnosed multiple myeloma
2026-526654-14-01Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised trial of ramantamig and daratumumab in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-free survival and 12-month MRD-negative complete response rate. Planned start Sep 2026; status: authorised.
02
Drugs
ramantamigdaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2026-526654-14-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526654-14-01.